131747-61-0

Basic information

• Product Name: (2-Trifluoromethyl-pyridin-4-yl)-methanol
• Synonyms: (2-Trifluoromethyl-pyridin-4-yl)-methanol;4-PyridineMethanol, 2-(trifluoroMethyl)-;2-(TrifluoroMethyl)-4-pyridineMethanol;[2-(Trifluoromethyl)pyridin-4-yl]methanol, 2-(Trifluoromethyl)isonicotinyl alcohol;4-(Hydroxymethyl)-2-(trifluoromethyl)pyridine
• CAS NO: 131747-61-0
• Molecular Formula: C₇H₆F₃NO
• Molecular Weight: 177.13
• Mol File: 131747-61-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 212.6 °C at 760 mmHg
• Flash Point: 82.4 °C
• Appearance: /
• Density: 1.362 g/cm³
• Vapor Pressure: 0.102mmHg at 25°C
• Refractive Index: 1.462
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: (2-Trifluoromethyl-pyridin-4-yl)-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2-Trifluoromethyl-pyridin-4-yl)-methanol(131747-61-0)
• EPA Substance Registry System: (2-Trifluoromethyl-pyridin-4-yl)-methanol(131747-61-0)

Safety Data

• Hazardous Substances Data: 131747-61-0(Hazardous Substances Data)

Usage

General Description

(2-Trifluoromethyl-pyridin-4-yl)-methanol is a chemical compound with the molecular formula C7H6F3NO. It is a white to off-white solid commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. (2-Trifluoromethyl-pyridin-4-yl)-methanol is known for its potential as an inhibitor for specific enzymes and is an important building block in the production of various drugs and pesticides. It has also been studied for its potential applications in the fields of organic synthesis and medicinal chemistry. Overall, (2-Trifluoromethyl-pyridin-4-yl)-methanol plays a crucial role in the development of important pharmaceutical and agricultural products.

InChI:InChI=1/C7H6F3NO/c8-7(9,10)6-3-5(4-12)1-2-11-6/h1-3,12H,4H2

Upstream product

• 887583-90-6 4-bromo-2-(trifluoromethyl)pyridine 
• 588702-68-5 2-trifluoromethyl-isonicotinic acid methyl ester 
• 131748-14-6 4-chloro-2-trifluoromethylpyridine 
• 131747-41-6 2-(trifluoromethyl)-4-pyridinecarboxylic acid 

Downstream Products

• 916304-20-6 2-trifluoromethyl-4-(aminomethyl)pyridine 
• 1227585-56-9 (2-trifluoromethylpyridin-4-yl)methyl bromide 
• 108338-12-1 2,6-Dimethyl-4-(2-trifluoromethyl-4-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester 
• 165558-80-5 methyl<<2-(trifluoromethyl)pyridin-4-yl>methyl>amine 
• 108338-20-1 2-(trifluoromethyl)pyridine-4-carbaldehyde 

Relevant articles and documents

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders

A set of novel Kv7.2/7.3 (KCNQ2/3) channel blockers was synthesized to address several liabilities of the known compounds XE991 (metabolic instability and CYP inhibition) and the clinical compound DMP 543 (acid instability, insolubility, and lipophilicity). Using the anthrone scaffold of the prior channel blockers, alternative heteroarylmethyl substituents were installed via enolate alkylation reactions. Incorporation of a pyridazine and a fluorinated pyridine gave an analog (compound 18, JDP-107) with a promising combination of potency (IC50 = 0.16 μM in a Kv7.2 thallium flux assay), efficacy in a Kv7.2/7.3 patch clamp assay, and drug-like properties.

TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE

Provided are quinoline carboxamide and quinoline carbonitrile compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1, R 2, L, X 1, X 2, and X 3, are as defined herein. The compounds of the invention, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising them, are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a person in need thereof for diseases or disorders in which the mGluR2-NAM receptor plays a causative role, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders.